Dealmakers' share-price performance trailed the MSCI World Index by five points, and deal volume sank as tensions left companies in wait-and-see mode.
They may, but new research surprisingly suggests that clawbacks may also prompt managers to drive down their companies' effective tax rates.
Ironwood Pharmaceuticals is in the black for the first time thanks to its complex spinoff of pre-commercial drug development programs.
Shares of deal-making companies worldwide underperform MSCI stock indices for a record seventh consecutive quarter.
Lead-generation firm Televerde puts purpose over profit by employing hundreds of incarcerated women to make sales calls and improve their lives.
While acquiring companies have underperformed stock indexes for the past two years, the outlook for M&A may be brightening.
While there are different ways to measure the success of M&A deals, shortly after deals close investors tend to expect they'll deliver incremental value.
Although acquisitions frequently fail, acquiring companies are ballyhooing their financial benefits as transaction prices steadily rise.
While it's not debatable that variance analysis is an important FP&A tool, companies differ in how they apply it.
Corporations should exist for a greater purpose than maximizing value to shareholders — and executives.
Is your company a golden goose, a unicorn, or a ship of the desert?
Private companies may benefit even more from a shareholder value focus than publicly listed companies do.
